BioSpace News Archive

CervoMed Inc. announced that it has entered into a definitive securities purchase agreement for a private placement to sell an aggregate of 2,532,285 units, each Unit comprised of one share of its common stock or one pre-funded warrant to purchase shares of its common stock, and in each case, one Series A warrant to purchase shares of its common stock to a select group of institutional and accredited healthcare specialist investors in a private placement.

Photocure ASA, The Bladder Cancer Company, announces the publication of the study “Racial Difference in Detection Rate of Bladder Cancer Using Blue Light Cystoscopy: Insights from a Multicenter Registry” in the journal Cancers this week.

Zoetis Inc. (NYSE:ZTS) will host a webcast and conference call at 8:30 a.m. (ET) on Thursday, May 2, 2024.

NanoVibronix, Inc., a medical device company that produces the UroShield®, PainShield® and WoundShield® Surface Acoustic Wave Portable Ultrasonic Therapeutic Devices, announced it has entered into an agreement with Veranex, Inc. to assist with the development of the company’s next generation UroShield and PainShield products.

Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”) today announced financial results for the fourth quarter and full year ended December 31, 2023, and a strategic prioritization initiative to focus resources on near-term milestones to support long-term shareholder value.

RefleXion Medical, Inc. and Limbus AI, Inc. announced a licensing agreement to incorporate Limbus’ automated contouring software, Limbus Contour, into the RefleXion® X1 radiotherapy treatment planning system.

Vaccines are one of the most significant public health achievements in modern history, playing a vital role in helping to prevent certain infectious diseases and protect communities across the globe.

Serum Detect, a cancer diagnostics company, is debuting a novel and promising approach for cancer early detection at the upcoming American Association for Cancer Research (AACR) conference.

ReAlta Life Sciences, Inc. (“ReAlta” or the “Company”) today announces that the company will be utilizing the preclinical services program offered by the National Institute of Allergy and Infectious Diseases (NIAID) to evaluate RLS-0071 as a medical countermeasure for Acute Radiation Syndrome (ARS).

Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today reported financial results for the year ended December 31, 2023 and provided a company update.